July 2018 - Buhlmann Diagnostics Corp

Month: July 2018

IBDoc – SwissMedtech Award Nominee

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test    About Swiss MEDTECH Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster.
Continue Reading

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading

Calprotectin Testing Goes Mobile

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article from Amanda Appleton, the Product Manager for Calprotectin at BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article     “App technology has the ability not only to improve the health of patients but
Continue Reading

IBDoc is Now Part of the TactioRPM

image credit: newswire.com US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries. The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the
Continue Reading

Join Us at AMLI 2018

We offer a comprehensive autoimmunity product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications.  Anti-MAG Autoantibodies ELISA  This assay is intended for the quantitative determination of human IgM-auto-antibodies directed against Myelin Associated Glycoprotein (MAG) in serum. Health Canada License: 89118 US: Research Use Only.  Not
Continue Reading

Join BUHLMANN at AACC 2018

BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing Health Canada License: 80726 US:  BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!) Health Canada Licenses: Quantum Blue®  fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not
Continue Reading